Jamjoom Pharmaceuticals Factory Company SJSC 4015.SR · SAR
Health Care · Tadawul · 🇸🇦 Saudi Arabia
112.80
—
Close of 9 Nov 2026, in SAR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jamjoom Pharmaceuticals Factory Company SJSC
Its shares trade on Tadawul under the ticker 4015.SR. It has been listed since 20 June 2023. In the fiscal year to 31 December 2025, it reported revenue of SAR 1.50bn and net income of SAR 463.8m. At that date it held total assets of SAR 2.05bn and shareholders' equity of SAR 1.72bn.
Jamjoom Pharma is pharmaceutical company. The firm operates two segments, which include pharmaceutical products, that represents medicines or drugs, which all are essential for the prevention and treatment of diseases, and protection of public health; and Consumer health products segment that represents the products sold directly to consumers. The Company’s subsidiaries include Al Jamjoom Pharma for Pharmaceutical Industries and Jamjoom Pharmaceutical Industry and Commerce Company Limited and the Company also operates approximately 8 branches.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Jun 2023
- Website
- jamjoompharma.com ↗
Leadership
Pay as last reported
- Mr. Mahmoud Yousuf Mohammed Salah JamjoomNon-Executive Chairman of the Board
- Mr. Tarek Youssef HosniChief Executive Officer
- Mr. Ahmed Yousuf Mohammed Salah JamjoomExecutive Vice Chairman of the Board
- Mr. Anwer MuhiddeinChief Financial Officer
- Mr. Alaa Abdelghany Mohammed GamaleldinVice President of Sales in Saudi Arabia, Gulf Region and Iraq
- Mr. Essam Jameel Al SayedGeneral Manager of Sales, Other Export Markets and Consumer Health Division
- Mr. Ali YehiaGeneral Manager of Sales and Egypt and North Africa
- Mr. Mazen Mosaad AlserihyCorporate Human Resources Director
- Mr. Ammar Abdulrahman Al AttasHead of the Legal Department
- Mr. Wagih Mohammed El BoklCommercial Director, since 2021
- Ms. Hala FathiGlobal Manufacturing Officer - Acting
- Mr. Mohammed Mahmoud JamjoomHead of Business Operations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates two segments: pharmaceutical products and consumer health products
- Owns subsidiaries including Al Jamjoom Pharma and Jamjoom Pharmaceutical Industry
- Maintains approximately 8 branches for operations
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market position provided
- No information on competitive advantages or unique capabilities
Opportunities
- Growth potential in pharmaceutical and consumer health markets
- Expansion through existing subsidiaries and branches
- Potential for increased market share in Saudi Arabia
Threats
- No specific threats identified in the provided information
- No mention of regulatory challenges or market competition
- No data on external economic or political factors
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.